Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States

JAMA Internal Medicine

Volumn 177, Issue 11, 2017, Pages 1613-1621

  Reddy, Krishna P ^a,b   Kong, Chung Yin ^a,b   Hyle, Emily P ^a,b   Baggett, Travis P ^a,b   Huang, Mingshu ^a,b   Parker, Robert A ^a,b   Paltiel, A David ^c   Losina, Elena ^b,d,e   Weinstein, Milton C ^b,f   Freedberg, Kenneth A ^a,b,e,f   Walensky, Rochelle P ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c YALE UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE; AGED; ANTIRETROVIRAL THERAPY; ARTICLE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEX; SMOKING; SMOKING CESSATION; STANDARD; TREATMENT REFUSAL; UNITED STATES; VERY ELDERLY; HIV INFECTIONS; LUNG TUMOR; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HIV INFECTIONS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING; SMOKING CESSATION; UNITED STATES;

EID: 85033547736     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.4349     Document Type: Article

References (62)

1. Smith CJ, Ryom L, Weber R, et al; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384 (9939):241-248. doi:10.1016/S0140 -6736(14)60604-8
2. Morlat P, Roussillon C, Henard S, et al; ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014; 28(8):1181-1191. doi:10.1097/QAD .0000000000000222
3. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335-344. doi:10.7326/M14 -0954
4. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824-835. doi:10 .1007/s10461-008-9449-2
5. Wilson SM, Pacek LR, Dennis PA, Bastian LA, Beckham JC, Calhoun PS. Veterans living with HIV: a high-risk group for cigarette smoking. AIDS Behav. 2017;21(7):1950-1955. doi:10.1007/s10461-017 -1717-6
6. Weinberger AH, Smith PH, Funk AP, Rabin S, Shuter J. Sex differences in tobacco use among persons living with HIV/AIDS: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2017;74(4):439-453. doi:10.1097/QAI .0000000000001279
7. Centers for Disease Control and Prevention, Office on Smoking and Health. Smoking and tobacco use: trends in current cigarette smoking among high school students and adults, United States, 1965–2011. https://www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking/. Accessed May 3, 2017.
8. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727-734. doi:10 .1093/cid/cis933
9. Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS. 2015;29(2):221-229. doi:10.1097 /QAD.0000000000000540
10. Reddy KP, Parker RA, Losina E, et al. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. J Infect Dis. 2016;214(11):1672-1681. doi:10.1093/infdis/jiw430
11. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26(8):1017-1025. doi:10.1097/QAD .0b013e328352d1ad
12. Hleyhel M, Hleyhel M, Bouvier AM, et al; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4). Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 2014;28(14):2109-2118. doi:10.1097 /QAD.0000000000000382
13. Yanik EL, Katki HA, Engels EA. Cancer risk among the HIV-infected elderly in the United States. AIDS. 2016;30(10):1663-1668. doi:10.1097 /QAD.0000000000001077
14. Shiels MS, Althoff KN, Pfeiffer RM, et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). HIV infection, immunosuppression, and age at diagnosis of non-AIDS-defining cancers. Clin Infect Dis. 2017;64(4):468-475. doi:10.1093/cid /ciw764
15. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24(9):1383-1388. doi:10.1200/JCO.2005.03 .4413
16. Kirk GD, Merlo C, O’ Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45(1):103-110. doi:10.1086/518606
17. Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr. 2010;55(4):510-515. doi:10 .1097/QAI.0b013e3181f53783
18. Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity and related disorders. Eur Respir J. 2015;46(6):1781-1795. doi:10.1183/13993003.00353-2015
19. Sigel K, Wisnivesky J, Crothers K, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV. 2017;4(2):e67-e73. doi:10 .1016/S2352-3018(16)30215-6
20. Vandenhende M-A, Roussillon C, Henard S, et al; ANRS EN20 Mortalité 2010 study group. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000. PLoS One. 2015;10(6):e0129550. doi:10.1371 /journal.pone.0129550
21. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344 (11):824-831. doi:10.1056/NEJM200103153441108
22. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586-595. doi:10.1056 /NEJMsa042088
23. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2): 84-92. doi:10.7326/0003-4819-158-2-201301150 00002
24. US Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed May 3, 2017.
25. Rosenberg MA, Feuer EJ, Yu B, et al. Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal. 2012;32(suppl 1):S25-S38. doi:10.1111/j.1539-6924.2011.01662.x
26. Galai N, Park LP, Wesch J, Visscher B, Riddler S, Margolick JB. Effect of smoking on the clinical progression of HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(5):451-458.
27. Ross EL, Weinstein MC, Schackman BR, et al. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015;60(7):1102-1110. doi:10.1093/cid/ciu1159
28. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321(7257):323-329. doi:10.1136/bmj.321 .7257.323
29. Crispo A, Brennan P, Jöckel K-H, et al. The cumulative risk of lung cancer among current, ex- and never-smokers in European men. Br J Cancer. 2004;91(7):1280-1286. doi:10.1038/sj.bjc.6602078
30. Silverberg MJ, Lau B, Achenbach CJ, et al; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163(7):507-518. doi:10.7326/M14 -2768
31. Centers for Disease Control and Prevention. HIV Surveillance Report, 2013; vol. 25. https://www.cdc.gov/hiv/library/reports /surveillance/. Accessed May 3, 2017.
32. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512-1520. doi:10.1086/652650
33. Walmsley SL, Antela A, Clumeck N, et al; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818. doi:10.1056/NEJMoa1215541
34. Raffi F, Rachlis A, Stellbrink H-J, et al; SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-743. doi:10.1016/S0140-6736 (12)61853-4
35. Raffi F, Jaeger H, Quiros-Roldan E, et al; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935. doi:10.1016 /S1473-3099(13)70257-3
36. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351-364. doi:10 .1056/NEJMsa1211127
37. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512. doi:10 .1210/jc.2006-2190
38. Freiberg MS, Chang C-CH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614-622. doi:10.1001/jamainternmed.2013.3728
39. Althoff KN, McGinnis KA, Wyatt CM, et al; Veterans Aging Cohort Study (VACS). Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60(4):627-638. doi:10.1093/cid /ciu869
40. National Cancer Institute. SEER Cancer Statistics Review 1975-2000. https://seer.cancer.gov/archive/csr/1975_2000/results_merged/sect _15_lung_bronchus.pdf. Accessed May 3, 2017.
41. Pleis J, Benson V, Schiller J. Summary health statistics for U.S. Adults: National Health Interview Survey, 2000. National Center for Health Statistics. Vital Health Stat. 2003;10(215). https://www.cdc.gov/nchs/data/series/sr_10/sr10_215.pdf. Accessed May 3, 2017.
42. Hyland A, Li Q, Bauer JE, Giovino GA, Steger C, Cummings KM. Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res. 2004;6(suppl 3):S363-S369. doi:10.1080/14622200412331320761
43. Rasmussen LD, Helleberg M, May MT, et al. Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. Clin Infect Dis. 2015;60 (9):1415-1423. doi:10.1093/cid/civ013
44. Samji H, Cescon A, Hogg RS, et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. doi:10.1371 /journal.pone.0081355
45. Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016; 73(1):39-46. doi:10.1097/QAI.0000000000001014
46. Tron L, Lert F, Spire B, Dray-Spira R; ANRS-Vespa2 study group. Tobacco smoking in HIV-infected versus general population in France: heterogeneity across the various groups of people living with HIV. PLoS One. 2014;9(9):e107451. doi:10.1371/journal.pone.0107451
47. US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. https://bphc.hrsa.gov/buckets/treatingtobacco.pdf. Accessed May 3, 2017.
48. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current cigarette smoking among adults—United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65(44):1205-1211. doi:10 .15585/mmwr.mm6544a2
49. Shahrir S, Tindle HA, McGinnis KA, et al. Contemplation of smoking cessation and quit attempts in human immunodeficiency virus-infected and uninfected veterans. Subst Abus. 2016;37(2):315-322. doi:10.1080/08897077.2015 .1062458
50. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388-395. doi:10 .1164/rccm.201006-0836OC
51. Clifford GM, Lise M, Franceschi S, et al; Swiss HIV Cohort Study. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer. 2012;106(3): 447-452. doi:10.1038/bjc.2011.558
52. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12):1152-1159. doi:10.1016 /S1470-2045(09)70282-7
53. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52(12):1458-1465. doi:10.1093/cid/cir207
54. Marcus JL, Leyden WA, Chao CR, et al. Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. AIDS. 2017;31(7):989-993. doi:10.1097/QAD .0000000000001434
55. Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1167-1173. doi:10.1158/1055-9965.EPI-14-1079
56. Sigel K, Crothers K, Dubrow R, et al. Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer. 2013;109(7):1974-1980. doi:10 .1038/bjc.2013.545
57. Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33(21):2376-2383. doi:10.1200/JCO.2014 .59.5967
58. Zucchetto A, Virdone S, Taborelli M, et al. Non-AIDS-defining cancer mortality: emerging patterns in the late HAART era. J Acquir Immune Defic Syndr. 2016;73(2):190-196. doi:10.1097/QAI .0000000000001033
59. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354(4):333-342. doi:10.1056/NEJMoa033250
60. Makinson A, Eymard-Duvernay S, Raffi F, et al; ANRS EP48 HIV CHEST study Team. Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. AIDS. 2016;30(4):573-582. doi:10.1097/QAD .0000000000000943
61. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338. doi:10.7326 /M13-2771
62. Siu AL; U.S. Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(8):622-634. doi:10.7326/M15-2023